Barely Significant
← all excerpts

Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.

J Immunother Cancer · 2024 · PMC10840060 · PMID 38309725

Europe PMCDOI
1
hedged sentence
0.0543
closest p · 1.1× alpha
0.0543
boldest claim

The sentences

showed a trendp value=0.0543so close (0.05 < p ≤ 0.1)
The latter correlation showed a trend ( EGFR wild-type vs mutant p value=0.0543) in agreement with previous reports 21 ( figure 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.